Infarmed is assessing the possibility of co-payment for obesity treatment medications, announced the Minister of Health on Wednesday, following new recommendations from the WHO regarding the disease. “It must be evaluated by experts and must fall within the guidelines set by the DGS for cases considered severe,” she said ...
Infarmed evaluates potential co-payment for obesity medications
Wednesday, 3 December 2025RSS
Context & Explainers
Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde) is Portugal’s national regulator for medicines and health products that approves drugs, monitors safety and enforces rules on pricing and reimbursement. In 2025 it approved 928 new medicines — 79% were generics, 38 were designated essential and 236 were national products — which affects which medicines are available and how much they cost at pharmacies.
